Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density.
In a cross-sectional study of 39 patients with medullary thyroid carcinoma (MTC), we have investigated the effects of long-term calcitonin excess on bone mineral density. Bone mineral density was measured by dual X-ray absorptiometry at the lumbar spine between the second and fourth vertebra and by single photon absorptiometry at the distal forearm. The mean observation time of each patient between diagnosis of tumour and measurement of bone mineral density was 62.4 months (range 1-158 months). The mean calcitonin serum level was 14.4 micrograms/l at the time of measurement of bone mineral density. All patients were substituted with 150-200 micrograms L-thyroxine daily. At both sites, the mean bone mineral densities of all patients with MTC were not significantly different from controls. Patients with normal calcitonin levels (below 0.2 micrograms/l) after treatment had a normal bone mineral density of the spine but significantly (P less than 0.05) reduced bone mineral density values of the forearm. This was due to the decreased body surface areas of patients in this subgroup. Patients with multiple endocrine neoplasia type IIa had significantly higher bone mineral densities. Other bone-influencing factors, such as postoperative hypoparathyroidism, calcium intake, diarrhoea, menopause, tumour stage, previous anti-tumour treatment, or thyroxine substitution dose, did not affect bone mineral density. We thus conclude that long-term excess of endogenous calcitonin in patients with MTC has no positive effect on bone mineral density.
Wüster
C
C
Department of Internal Medicine I, Endocrinology and Metabolism, Ruprecht-Karls-Universität Heidelberg, Germany.
Raue
F
F
Meyer
C
C
Bergmann
M
M
Ziegler
R
R
D015502:Absorptiometry, Photon; D000328:Adult; D015519:Bone Density / Q000502:physiology*; D002116:Calcitonin / Q000097:blood / Q000378:metabolism*; D002277:Carcinoma / Q000097:blood / Q000378:metabolism*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008593:Menopause / Q000097:blood; D008875:Middle Aged; D009377:Multiple Endocrine Neoplasia / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000097:blood / Q000378:metabolism*; D013997:Time Factors
D002116:Calcitonin